Phase 2 Transfusion Clinical Trials
9 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–9 of 9 trials
Recruiting
Phase 2
A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body
Non-Transfusion Dependent Beta-Thalassemia (NTDT)
Regeneron Pharmaceuticals95 enrolled26 locationsNCT06421636
Recruiting
Phase 2
Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients
Transfusion-dependent β-thalassemia Patients
Rongrong Liu78 enrolled8 locationsNCT07338344
Recruiting
Phase 2Phase 3
IntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study
Surgery--ComplicationsIron-deficiencySpinal Fusion+4 more
Columbia University120 enrolled1 locationNCT07217873
Recruiting
Phase 1Phase 2
Study of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness
Platelet Transfusion Refractoriness
Keymed Biosciences Co.Ltd110 enrolled1 locationNCT06792019
Recruiting
Phase 2
Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.
Allergic Transfusion Reaction
Institute of Hematology & Blood Diseases Hospital, China6,642 enrolled4 locationsNCT04688736
Recruiting
Phase 1Phase 2
Β-Thalassemia Treatment with KL003 Cell Injection
Transfusion Dependent Beta-Thalassemia
Kanglin Biotechnology (Hangzhou) Co., Ltd.41 enrolled2 locationsNCT06280378
Recruiting
Phase 2
Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD
Myelodysplastic SyndromesAnemiaTransfusion-dependent Anemia+1 more
Associazione Qol-one22 enrolled23 locationsNCT05924100
Recruiting
Phase 2
Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia
Transfusion Dependent Thalassemia
Rongrong Liu396 enrolled5 locationsNCT06657391
Recruiting
Phase 2
Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness
Severe Aplastic AnemiaPlatelet Transfusion Refractoriness
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT06254560